Abstract

Research Article

Cost Assessment of Corticosteroid Therapy for Corticosteroid-sensitive Dermatoses in a Resource-limited Country

Karabinta Y*, Konaté M, Karambé T, Keita ACF, Dicko A, Traoré C, Sylla O, Coulibaly S, Gassama M, Koné C, Dissa L and Pr Kéita S

Published: 07 February, 2024 | Volume 8 - Issue 1 | Pages: 004-006

Introduction: Corticosteroid therapy is widely used in dermatology for treating various conditions. In France, the cost of corticosteroid treatment varies, and in Mali, a significant prevalence of corticosteroid-treated diseases has been reported. Given the prolonged treatment duration often required, understanding the cost implications in resource-limited settings is crucial.
Patients and methods: This descriptive cross-sectional study took place at the dermatology department of the University Hospital Center of Dermatology in Bamako. Data were prospectively collected from patients undergoing corticosteroid therapy over one year. Variables included sociodemographic data, clinical information, and medication costs.
Results: During the study period, 24 cases of dermatoses treated with corticosteroids were identified among 125 hospitalized patients, representing a prevalence of 19.2%. Most patients were women (58.3%), with an average age of 37.5 years. Lichen planus (54.2%) and pemphigus (37.5%) were the most common pathologies. Many patients had extensive lesions before treatment, but the majority responded well to corticosteroids.
Discussion: Despite study limitations, such as its descriptive nature, it provided valuable insights into the economic evaluation of long-term corticosteroid therapy. The predominance of women, the age distribution, and the prevalence of specific dermatoses were highlighted. The study also revealed the substantial financial burden of corticosteroid treatment, primarily driven by direct costs.
Conclusion: The study underscores the financial challenges associated with long-term corticosteroid therapy in dermatology in Mali. The high costs adversely affect patients and their families, especially considering the socioeconomic status of many patients. Moreover, the findings emphasize the importance of comprehensive care strategies and the need for accessible healthcare solutions to address these challenges effectively.

Read Full Article HTML DOI: 10.29328/journal.adr.1001031 Cite this Article Read Full Article PDF

Keywords:

Cost assessment; Corticosteroid therapy; Resource-limited country

References

  1. Chasidow O, Etienne SD, Herson S. General corticosteroid therapy: In Louis D. dermatological therapy. Paris, Flammarion Medicine-Science. 1991 edition 726-735.
  2. Denis A, Froin-Dencausse M. Practice leaders (corticosteroid therapy) Paris: MSD/Merck. Sharp and Dohme. Chibert, 1978 edition; 305.
  3. Rekkab S. AMAL. General corticosteroid therapy in dermatology. Medicine Thesis, 2008; 72.
  4. Sidibe A. Autoimmune Pemphigus in Dermatology at CNAM, Medical Thesis Bamako: 2008; 35; 73.
  5. Food and Drug Administration. Paying for health care from the household perspective USA: American Journal of Health Economics, 2007 edition, 26-28.
  6. Royal Health Academy. Public Health Expenditure Canada: Journal of Health Economics and Policy (Laval University), 2007 edition; 335-345.
  7. Moutel G, Herve C. Evaluation of medical care practices in INSERM Paris: Presse Médicale, 2001 edition; 84.
  8. Phelps C. Fundamentals of Health Economics, publ-Union Paris: nouveaux horizons, 1995; 40-64.
  9. Fekih M, Chaieb A, Sboui H, Denguezli W, Hidar S, Khairi H. Feasibility, effects, and cost of antenatal corticosteroid therapy in the prevention of hyaline membrane disease in premature newborns Tunis: Health Economics, 2002 edition; 260–265.
  10. Kamara M. Pharmaco-epidemiological study of the side effects of corticosteroid therapy Pharmacy Thesis Bamako: 2000; 75; 75.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?